HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintained a $15 price target for the company's stock.
November 28, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barinthus Biotherapeutics has been given a continued Buy rating and a $15 price target by HC Wainwright & Co., indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst like Yi Chen could lead to increased investor confidence in BRNS, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100